Systematic Identification of Familial Hypercholesterolaemia in Primary Care-A Systematic Review

Luisa Silva1, Nadeem Qureshi1, Hasidah Abdul-Hamid1,2

  • 1Primary Care Stratified Medicine (PRISM) Group, NIHR School of Primary Care Research, University of Nottingham, Nottingham NG7 2RD, UK.

Insights

Systematic identification of familial hypercholesterolaemia (FH) in primary care shows limited effectiveness. On-screen prompts in electronic health records offer a small increase in identifying definite FH, but more research is needed.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Public Health

Background:

  • Familial hypercholesterolaemia (FH) is an inherited condition leading to premature cardiovascular disease.
  • The majority of FH patients remain undiagnosed, highlighting a critical gap in detection.
  • Effective strategies for systematic FH identification in primary care are needed.

Purpose of the Study:

  • To systematically review interventions for identifying FH in primary care settings.
  • To assess the effectiveness of different methods for FH case finding.
  • To evaluate strategies for improving the diagnosis of FH in non-specialist healthcare environments.

Main Methods:

  • Systematic review of intervention studies for FH identification in primary care.
  • Inclusion of three non-randomized intervention studies.
  • Analysis of interventions including electronic health record prompts, laboratory result comments, postal invitations, and outreach nurse assessments.

Main Results:

  • On-screen prompts in electronic health records were used in all included studies for systematic FH identification.
  • No significant increase in definite FH identification was observed with prompts combined with postal invitations (Simon-Broome criteria), though possible FH identification increased by 25.4%.
  • On-screen prompts alone showed a small increase in definite FH identification (0.05%), but combining them with an outreach nurse did not yield significant improvements.

Conclusions:

  • There is insufficient evidence to determine the most effective method for systematically identifying FH in primary care.
  • On-screen prompts show potential but require further investigation regarding their optimal implementation and impact.
  • Adverse effects were not reported in the included studies, suggesting interventions are likely safe.

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
133
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
961
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
91
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
441
Primary Healthcare Services01:30

Primary Healthcare Services

Primary care promotes wellness and prevents disease. This care includes health promotion, education, protection (such as immunizations), early disease screening, and environmental considerations. Settings providing this type of healthcare include physician offices, public health clinics, school nursing, and community health nursing.
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
1.7K